Assessing postural control and postural control strategy in diabetes patients using innovative and wearable technology.
Bijan Najafi, Deena Horn, Samuel Marclay...
https://pubmed.ncbi.nlm.nih.gov/20663438/Actively Recruiting
Led by Hamad Medical Corporation · Updated on 2022-06-07
100
Participants Needed
2
Research Sites
3 weeks
Total Duration
Researchers are investigating the use of plantar electrical stimulation during hemodialysis to improve balance, mobility, and quality of life in patients with diabetes who also have chronic kidney failure. The study addresses the high prevalence of diabetes and related complications, including poor balance and foot problems, especially in those undergoing hemodialysis. The intervention aims to reduce risks like diabetic foot ulcers and peripheral arterial disease, which are common and serious issues in this population.
CONDITIONS
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility
F
Fadwa Al-Ali, MD
A
Abdullah Hamad, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hamad Medical Corporation
Lead Sponsor
Qatar National Research Fund
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Plantar Electrical Stimulation | Sham Comparator (Inactive Device) | Standard Care |
|---|---|---|---|
| What it is | A therapeutic intervention using the Tennant Biomodulator® device to deliver plantar electrical stimulation through the soles of the feet during hemodialysis sessions. | An inactive sham procedure where an identical device is applied but delivers no electrical stimulation during hemodialysis. | Current typical management does not include therapeutic plantar electrical stimulation during hemodialysis for adults with diabetes and peripheral neuropathy. |
| Role in the trial | Evaluated as the active intervention to determine effects on balance, mobility, and related outcomes. | Serves as the randomized control group to distinguish device effects from placebo or non-specific effects. | Reflects the absence of device-based plantar electrical stimulation, representing routine supportive care during hemodialysis. |
| Primary use | To test whether therapeutic electrical stimulation can improve balance, walking speed, gait, and related complications in individuals with diabetes and peripheral neuropathy on hemodialysis. | Used as an inactive control to separate the effects of active stimulation from non-specific treatment effects. | Routine supportive care aims to manage symptoms and prevent complications in adults with diabetes on hemodialysis but does not specifically target balance and gait outcomes through device-based stimulation. |
| How it is given or performed | The device is placed on the plantar (sole) surface of each foot using TENS electrodes, activated at the start of hemodialysis and left to run automatically for each therapy session. | The same device is applied with identical electrodes but is not activated to deliver electrical stimulation. | Participants receive hemodialysis without any additional device-based plantar electrical stimulation. |
| Evidence status | The effectiveness of plantar electrical stimulation for improving balance, gait, or mobility in diabetic patients on hemodialysis is investigational. Results from this trial are not yet established. | No established therapeutic effect is expected from the inactive sham device; it is designed to serve as a placebo comparator. | Balance, mobility, and risk of falls in adults with diabetes and neuropathy remain significant concerns under current standard care. Non-device exercise interventions like balance training have shown some benefit, but routine adjunctive device-based stimulation is not supported by current evidence. |
| Important limitations | Long-term safety and real-world effectiveness for balance and gait in diabetic patients on hemodialysis are not yet established, and larger studies are needed. | Sham comparator does not reflect standard care outside clinical research and cannot address the benefit over usual practice. | Current care does not specifically address balance, gait, or fall risk with device-based electrical stimulation, and many patients remain at risk despite standard supportive management. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive plantar electrical stimulation treatment during hemodialysis sessions to improve balance and mobility. Sessions last one hour and occur three times per week for 12 weeks.
Three visits per week during hemodialysis sessions
Duration - 2 weeks
Participants are observed for two weeks following the treatment phase to evaluate retention of intervention effects.
No specific visits beyond hemodialysis sessions
Duration - 12 months
Participants are followed for 12 months after the intervention to monitor falls, diabetic foot ulcers, limb amputation, and diabetes-related complications.
Periodic follow-up assessments over 12 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Bijan Najafi, Deena Horn, Samuel Marclay...
https://pubmed.ncbi.nlm.nih.gov/20663438/Samantha Richerson, Kyle Rosendale
https://pubmed.ncbi.nlm.nih.gov/17561798/L Vileikyte
https://pubmed.ncbi.nlm.nih.gov/11544609/Joseph W Lemaster, Michael J Mueller, Gayle E Reiber...
https://pubmed.ncbi.nlm.nih.gov/18801859/Bijan Najafi, David G Armstrong, Jane Mohler
https://pubmed.ncbi.nlm.nih.gov/24124940/James S Wrobel, Bijan Najafi
https://pubmed.ncbi.nlm.nih.gov/20663446/L Allet, S Armand, R A de Bie...
https://pubmed.ncbi.nlm.nih.gov/19921145/Donna Flahr
https://pubmed.ncbi.nlm.nih.gov/21030727/Kirsten L Johansen
https://pubmed.ncbi.nlm.nih.gov/26656296/Abdulbari Bener, Mahmoud Zirie, Ibrahim M Janahi...
https://pubmed.ncbi.nlm.nih.gov/19261345/Hamad Medical Corporation
Lead Sponsor
Qatar National Research Fund
Collaborating Sponsor